We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Early Detection Identified for Leukemia Patients' Resistance to Therapy

By LabMedica International staff writers
Posted on 25 Aug 2016
Print article
Image: The Rotor-Gene real-time PCR system (Photo courtesy of Qiagen).
Image: The Rotor-Gene real-time PCR system (Photo courtesy of Qiagen).
A world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia has been made. The discovery offers some hope that the patients' treatment could be changed sooner to improve their chances of survival.

Tyrosine kinase inhibitor (TKI) therapy results in excellent responses in the majority of patients with chronic myeloid leukemia. First-line imatinib treatment, with selective switching to nilotinib when patients fail to meet specific molecular targets or for imatinib intolerance, results in excellent overall molecular responses and survival.

A team of scientists led by those at the University of Adelaide (Australia) obtained peripheral blood from consenting patients before commencement of imatinib therapy (day 1) and at post-therapy time points specified in the TIDEL II (Therapeutic Intensification in DE-novo Leukemia II) protocol (for example, day 22, imatinib cessation). Patient cells were collected at time points defined in the TIDEL II treatment schema: total white cells were isolated by ammonium chloride lysis for determination of ATP Binding Cassette Subfamily B Member 1 (ABCB1) messenger ribonucleic acid (mRNA) levels and frozen, mononuclear cells were isolated from whole blood by Ficoll gradient.

Real time quantitative polymerase chain reaction was performed and amplified on a (Corbett Research, San Francisco, CA, USA). BCR-ABL1 mRNA expression levels were quantitated using the TaqMan Universal PCR Master Mix and the ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, Ca, USA). The team's work showed for the first time, that assessing a patient's levels of the P-glycoprotein soon after they start receiving Glivec therapy will help to predict that patient's long-term response to the drug.

The authors concluded that analysis of expression levels at diagnosis and after three weeks undergoing imatinib therapy (day 22) highlights the potential importance for monitoring increases in ABCB1 mRNA expression early in therapy to predict those patients likely to achieve poor molecular responses. An increase in levels of ABCB1 mRNA may serve as an easily translatable early warning assay for loss of response/development of resistance to imatinib.

Laura N. Eadie, PhD, the lead author of the study said, “Some patients were found to have higher levels of P-glycoprotein in their leukemic cells after just a few weeks of starting therapy. These patients were much more likely to develop resistance to Glivec later on. We've found the greater the increase in P-glycoprotein in patients, the greater their risk is of becoming resistant and not responding to their drug any more, or even succumbing to their disease.” The study was published on July 15, 2016, in the journal Leukemia.

Related Links:
University of Adelaide
Corbett Research
Applied Biosystems
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.